Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List (ARCADIA-HF)

Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List: a Multicenter, Double-blind, Randomized Clinical Trial.

In the DAPA-HF trial, the use of dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2), reduced significantly the risk of worsening heart failure or death from cardiovascular causes compared to placebo among patients with heart failure (HF) and a reduced ejection fraction. This new drug offers a very potent and interesting therapeutic pathway since it reduces clinical congestion, it preserves glomerular renal function, does not appear to cause symptomatic clinical hypotension and improves symptoms and quality of life compared to placebo.

Advanced heart failure patients with reduced ejection fraction represent a small and severe subgroup of heart failure of patients with frequent worsening heart failure events and high rates of death. The effect of dapagliflozin in this subgroup of patients was not assessed in the DAPA-HF study. The therapeutic profile of SGLT2 inhibitors appears to be of high interest, since this group of patients has a poor tolerance to usual heart failure drugs, frequent worsening renal function and congestive symptoms persistence with poor quality of life scores.

Soluble urokinase-type plasminogen activator receptor (suPAR) is a signaling glycoprotein considered to be involved in the pathogenesis of kidney disease. It is associated with the risk of acute kidney injury in different clinical and experimental situation. It is also a new validated biomarker predictive of adverse clinical outcome in heart failure patients. This biomarker allows a better risk stratification in heart failure patients after adjustment for Nt-proBNP.

As a useful biomarker implicated in both heart failure and acute kidney injury, suPAR seems to be an interesting biomarker to assess cardio-renal benefits of dapagliflozin.

The aim of this study is to investigate if a treatment by dapagliflozin reduces significantly suPAR compared to placebo in a population of advanced heart failure patients, candidates to heart transplantation. The effect of dapagliflozin compared to placebo will also be assessed on other secondary heart failure outcomes in this patient population.

Study Overview

• Status: Withdrawn
• Conditions: End-stage Heart Failure
• Intervention / Treatment: Drug: Dapagliflozin 10mg; Drug: Placebo

• Study Type: Interventional
• Phase: Phase 2

Contacts and Locations

Study Locations

• France
  • Bron, France, 69677
    • Hôpital Pneumologique et Cardiovasculaire Louis Pradel

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patient has signed informed consent form
2. Age ≥ 18 years
3. NYHA class ≥3
4. LVEF ≤ 35%
5. On optimal medical management (OMM) based on current heart failure practice guidelines at maximal tolerated dose for at least 30 days
6. On waiting list for heart transplantation after multidisciplinary Heart Team decision, with anticipated access to heart transplant ≥ 6 months

Exclusion Criteria:

1. Priority patient on waiting list for heart transplantation
2. Etiology of heart failure due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis or restrictive cardiomyopathy
3. Inotrope dependent, existence of ongoing mechanical circulatory support
4. Current acute decompensated HF or hospitalization due to decompensated HF <30 days prior to the enrolment
5. History of any organ transplant or prior implantation of a ventricular assistance device (VAD) or similar device, or implantation expected after randomization
6. Presence of an active, uncontrolled infection
7. Any recent interventional procedure likely to improve symptoms and heart failure status (coronary revascularization, percutaneous mitral valve intervention, cardiac resynchronization therapy) < 60 days
8. Glomerular filtration rate < 30 ml/min/1.73 m2, according to CKD-EPI formula
9. Unstable or rapidly progressing renal disease
10. Patients with severe hepatic impairment (Child-Pugh class C)
11. Chronic treatment with dapagliflozin or other SGLT2 inhibitors
12. Patient with known history of severe drug intolerance to dapagliflozin or any excipients of the dapagliflozin (galactose, lactase)
13. Type 1 diabetes mellitus
14. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or extraction of study drug at investigators' discretion
15. Participation in another clinical interventional trial
16. Any condition other than heart failure that could limit survival to less than 24 months
17. Positive pregnancy test if of childbearing potential or refusal to use adequate contraception or women breast-feeding
18. Patients with any legal protection measure
19. Patients without any health coverage
20. Psychiatric disease/disorder, irreversible cognitive dysfunction or psychological issues that are likely to impair compliance

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Control group	Drug: Placebo; Patients randomized in the control group will receive during 6 months, placebo once daily per oral route, in addition to the optimal medical management based on current heart failure practice guidelines.
Experimental: Treatment group Daplagliflozin	Drug: Dapagliflozin 10mg; The intervention group will receive, during 6 months, dapagliflozin per oral route at a dose of 10 mg once daily in addition to the optimal medical management based on current heart failure practice guidelines.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Levels of suPAR (ng/ml)	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
VO2 max assessment	VO2 max assessment to evaluate the functional status	6 months
cardiac output assessed by right heart catheterization	The impact of dapagliflozin on hemodynamic parameters between baseline and 6 months assessed by right heart catheterization hemodynamic parameters	6 months
pulmonary capillary wedge pressure assessed by right heart catheterization	The impact of dapagliflozin on hemodynamic parameters between baseline and 6 months assessed by right heart catheterization hemodynamic parameters	6 months
pulmonary artery systolic and mean pressure assessed by right heart catheterization	The impact of dapagliflozin on hemodynamic parameters between baseline and 6 months assessed by right heart catheterization hemodynamic parameters	6 months
mean pressure assessed by right heart catheterization	The impact of dapagliflozin on hemodynamic parameters between baseline and 6 months assessed by right heart catheterization hemodynamic parameters	6 months
right atrial pressure assessed by right heart catheterization	The impact of dapagliflozin on hemodynamic parameters between baseline and 6 months assessed by right heart catheterization hemodynamic parameters	6 months
Left Ventricular Ejection Function assessed by echocardiography	The impact of dapagliflozin on echocardiographic parameters between baseline and 6 months	6 months
Left ventricular end-diastolic diameter assessed by echocardiography	The impact of dapagliflozin on echocardiographic parameters between baseline and 6 months	6 months
Left ventricular end systolic volume assessed by echocardiography	The impact of dapagliflozin on echocardiographic parameters between baseline and 6 months	6 months
mitral regurgitation grade assessed by echocardiography	The impact of dapagliflozin on echocardiographic parameters between baseline and 6 months	6 months
left atrial volume assessed by echocardiography	The impact of dapagliflozin on echocardiographic parameters between baseline and 6 months	6 months
Nt-proBNP level		6 months
Creatinine level		6 months
Quality of life assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)		6 months

Collaborators and Investigators

• Sponsor: Hospices Civils de Lyon
• Investigators: Principal Investigator: Guillaume BAUDRY, Dr, Hospices Civils de Lyon

Study record dates

Study Major Dates

• Study Start (Estimated): September 1, 2022
• Primary Completion (Estimated): April 1, 2024
• Study Completion (Estimated): April 1, 2024

Study Registration Dates

• First Submitted: March 1, 2021
• First Submitted That Met QC Criteria: March 3, 2021
• First Posted (Actual): March 4, 2021

Study Record Updates

• Last Update Posted (Actual): August 7, 2023
• Last Update Submitted That Met QC Criteria: August 3, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: Dapagliflozin; End-stage heart failure,; Cardio-renal syndrome
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Failure; Hypoglycemic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Sodium-Glucose Transporter 2 Inhibitors; Dapagliflozin
• Other Study ID Numbers: 69HCL20_1135; 2020-005713-40 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No